Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. by Krueger, James G. et al.
Himmelfarb Health Sciences Library, The George Washington University
Health Sciences Research Commons
Dermatology Faculty Publications Dermatology
6-1-2016
Cutaneous Adverse Events in the Randomized,
Double-Blind, Active-Comparator DECIDE Study
of Daclizumab High-Yield Process Versus
Intramuscular Interferon Beta-1a in Relapsing-
Remitting Multiple Sclerosis.
James G. Krueger
Leon Kircik
Firas Hougeir
Adam J. Friedman
George Washington University
Xiaojun You
See next page for additional authors
Follow this and additional works at: http://hsrc.himmelfarb.gwu.edu/smhs_derm_facpubs
Part of the Dermatology Commons
This Journal Article is brought to you for free and open access by the Dermatology at Health Sciences Research Commons. It has been accepted for
inclusion in Dermatology Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please
contact hsrc@gwu.edu.
APA Citation
Krueger, J. G., Kircik, L., Hougeir, F., Friedman, A. J., You, X., & + 6 more (2016). Cutaneous Adverse Events in the Randomized,
Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in
Relapsing-Remitting Multiple Sclerosis.. Advances in Therapy, (). http://dx.doi.org/10.1007/s12325-016-0353-2
Authors
James G. Krueger, Leon Kircik, Firas Hougeir, Adam J. Friedman, Xiaojun You, and + 6 more
This journal article is available at Health Sciences Research Commons: http://hsrc.himmelfarb.gwu.edu/smhs_derm_facpubs/36
ORIGINAL RESEARCH
Cutaneous Adverse Events in the Randomized,
Double-Blind, Active-Comparator DECIDE Study
of Daclizumab High-Yield Process Versus
Intramuscular Interferon Beta-1a in Relapsing-
Remitting Multiple Sclerosis
James G. Krueger . Leon Kircik . Firas Hougeir . Adam Friedman .
Xiaojun You . Nisha Lucas . Steven J. Greenberg . Marianne Sweetser .
Wanda Castro-Borrero . Peter McCroskery . Jacob Elkins
Received: March 30, 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: Cutaneous adverse events (AEs)
have been observed in clinical studies of
daclizumab high-yield process (HYP) in
relapsing-remitting multiple sclerosis (RRMS).
Here, we report cutaneous AEs observed in the
randomized, double-blind, active-comparator
DECIDE study (ClinicalTrials.gov identifier,
NCT01064401).
Methods: DECIDE was a randomized,
double-blind, active-controlled phase 3 study
of daclizumab HYP 150 mg subcutaneous every
4 weeks versus interferon (IFN) beta-1a 30 mcg
intramuscular (IM) once weekly in RRMS.
Treatment-emergent AEs were classified and
recorded by investigators. Investigators also
assessed the severity of each AE, and whether
it met the criteria for a serious AE. Cutaneous
AEs were defined as AEs coded to the Medical
Dictionary for Regulatory Activities System
Organ Class of skin and subcutaneous tissue
disorders. The incidence, severity, onset,
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resolution, and management of AEs were
analyzed by treatment group.
Results: Cutaneous AEs were reported in 37%
of daclizumab HYP-treated patients and 19% of
IFN beta-1a-treated patients. The most common
investigator-reported cutaneous AEs with
daclizumab HYP were rash (7%) and eczema
(4%). Most patients with cutaneous AEs
remained on treatment (daclizumab HYP,
81%; IM IFN beta-1a, 90%) and had events
that were mild or moderate (94% and 98%) and
subsequently resolved (78% and 82%). Most
patients with cutaneous AEs did not require
treatment with corticosteroids or were treated
with topical corticosteroids (daclizumab HYP,
73%; IM IFN beta-1a, 81%). Serious cutaneous
AEs were reported in 14 (2%) daclizumab HYP
patients and one (\1%) IM IFN beta-1a patient.
Conclusion: There was an increased risk of
cutaneous AEs with daclizumab HYP. While
physicians should be aware of the potential for
serious cutaneous AEs, the typical cutaneous
AEs were mild-to-moderate in severity,
manageable, and resolved over time.
Funding: Biogen and AbbVie Biotherapeutics
Inc.
Trial registration: ClinicalTrials.gov identifier,
NCT01064401.
Keywords: Cutaneous events; Daclizumab
high-yield process; Dermatology; Interferon
beta; Neurology; Relapsing-remitting multiple
sclerosis; Safety
INTRODUCTION
Daclizumab high-yield process (HYP) is a
humanized monoclonal antibody targeted
against CD25, the interleukin 2 receptor alpha
subunit [1]. Interleukin 2 is a cytokine produced
by activated T cells that regulates both immune
responses and the maintenance of self-tolerance
[2].BlockadeofCD25showedpromising results in
T cell-mediated autoimmunedisorders, including
in pilot studies in multiple sclerosis (MS) [3–5].
Subsequently, the efficacy and safety of
daclizumab HYP have been evaluated in clinical
studies in relapsing-remitting MS (RRMS) [6, 7].
In the pivotal 1-year SELECT study
(ClinicalTrials.gov identifier, NCT00390221),
daclizumab HYP 150 mg subcutaneous (SC)
every 4 weeks significantly reduced relapses,
12-week confirmed disability progression, and
brain lesions on magnetic resonance imaging
(MRI) compared with placebo [6]. Daclizumab
HYP also showed superior efficacy to interferon
(IFN) beta-1a 30 mcg intramuscular (IM) once
weekly with respect to annualized relapse rate,
MRI lesion activity, and 24-week confirmed
disability progression over 2–3 years of
treatment in the active-comparator phase 3
DECIDE study (ClinicalTrials.gov identifier,
NCT01064401) [7]. Based on the safety profile
of daclizumab HYP in SELECT [6], one of the
adverse events (AEs) of interest in DECIDE was
cutaneous AEs. The objective of this report is to
provide a description of the frequency and
character of cutaneous AEs in DECIDE.
METHODS
Standard Protocol Approvals,
Registrations, and Patient Consents
The DECIDE study protocol was approved by
central and local ethics committees, and the
S. J. Greenberg
AbbVie, 1 North Waukegan Road, North Chicago,
IL 60064, USA
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study was conducted in accordance with the
International Conference on Harmonisation
Guideline for Good Clinical Practice and the
Declaration of Helsinki of 1964, as revised in
2008 [8]. DECIDE was registered at
ClinicalTrials.gov (NCT01064401). All patients
provided written informed consent before
participating in the study and before
photographs were used for educational
purposes.
Trial Design and Patients
DECIDE was a multicenter, randomized,
double-blind, double-dummy, active-controlled,
phase 3 study to evaluate the efficacy and safety of
daclizumab HYP versus IM IFN beta-1a [7]. The
study design and patient eligibility criteria have
beenpreviously reported [7]. Briefly, patientswith
a confirmed diagnosis of RRMS (2005 McDonald
criteria 1–4) [9] were randomized 1:1 to receive
daclizumab HYP 150 mg SC every 4 weeks or IFN
beta-1a 30 mcg IMonceweekly for aminimumof
96 weeks up to a maximum of 144 weeks. The
study ended when the last enrolled patient
completed 96 weeks of treatment.
Safety Assessments
Treatment-emergent AEs and serious AEs, defined
as events that started after the first dose of study
drug and up to 180 days after the last dose, were
monitored, classified, and recorded by
investigators throughout the study. Serious AEs
were followed until the event resolved, stabilized,
or returned to baseline, even in patients who had
completed or discontinued the study.
Investigators assessed AE severity (mild,
moderate, severe), whether AEs and serious AEs
were or were not related to study treatment, and
whether an AE met the criteria for a serious AE
based on guidance in the protocol (please see
Table S1 in the supplementary material for
details). A serious AE was an AE that resulted in
hospitalization/prolongation of hospitalization,
disability/incapacity, a congenital anomaly/birth
defect, or death, or in the opinion of the
investigator was life-threatening. Medical
history of rash, dermatitis, eczema, or psoriasis
was derived from a search of patients’ medical
history obtained at enrollment.
An independent central dermatologist
blinded to study treatment reviewed and
provided assessments of clinically significant
events and the overall pattern of cutaneous AEs
to the study’s data safety monitoring board. In
addition, guidelines for the management of
patients with cutaneous AEs were developed
and provided to the study investigators,
although implementation of these guidelines
was not mandated by the protocol (see
Appendix S1).
To provide a visual frame of reference,
photographs of mild, moderate, and severe
events in daclizumab HYP-treated patients
were selected for inclusion in the
manuscript from a limited subset for which
patients had provided written consent for
educational use.
Data Analyses
Cutaneous AEs were defined as all events coded
to the Medical Dictionary for Regulatory
Activities (MedDRA; version 16.1) System
Organ Class of skin and SC tissue disorders.
This System Organ Class does not include the
Preferred Terms directly related to injection site
reactions. The incidence of AEs was analyzed
based on treatment group.
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RESULTS
Patients and Study Drug Exposure
DECIDE enrolled 1841 patients with RRMS; 919
were randomized and treated with daclizumab
HYP and 922 were treated with IM IFN beta-1a.
At baseline, patient demographic and clinical
characteristics were similar between treatment
groups [7]. Briefly, 68% of patients were female,
90% were white, and 41% had received prior
treatment with disease-modifying therapies in
each treatment group. In the daclizumab HYP
and IM IFN beta-1a groups, the mean (standard
deviation) age was 36.4 (9.4) and 36.2 (9.3)
years, respectively. At baseline, 16% of patients
in each treatment group had a medical history
of a dermatological condition.
The mean (median) time on treatment was
102.0 (108.7; range 0.1–145.3) weeks and 100.5
(111.4; range 0.1–146.1) weeks in the
daclizumab HYP and IM IFN beta-1a groups,
representing 1797.2 and 1776.6 patient-years of
treatment exposure, respectively.
Cutaneous AE Onset and Severity
Treatment-emergent cutaneous AEs were
reported at generally stable rates in both
groups when analyzed by 12-week intervals
over 96 weeks of treatment, although the rates
were consistently higher with daclizumab HYP
than with IM IFN beta-1a (Fig. 1a). The
cumulative incidence of cutaneous AEs was
37% in the daclizumab HYP group compared
with 19% in the IM IFN beta-1a group over the
course of the study. During the 6-month period
after the last dose of study treatment, the
incidence of cutaneous AEs remained higher
in the daclizumab HYP group (21%) compared
with the IM IFN beta-1a group (5%), but was
similar between the groups beyond 6 months
after the last dose (daclizumab HYP,\1%; IM
IFN beta-1a, \1%). Cutaneous AEs were more
frequently assessed by the investigator as being
related to study treatment in daclizumab
HYP-treated patients (15%) than in IM IFN
beta-1a-treated patients (7%).
The most common cutaneous AEs (C2% of
patients in either treatment group) are listed in
Table 1. Dermatitis, eczema, and rashes were
among the most common investigator-reported
Preferred Terms for cutaneous AEs (Table 1).
There was a 1.5- to 2.0-fold higher incidence of
cutaneous AEs in patients with a medical
history of rash, dermatitis, eczema, or psoriasis
Fig. 1 Incidence of all cutaneous AEs (a) and moderate or
severe cutaneous AEs (b) by 12-week intervals during the
treatment period. The numbers of patients represents the
safety population evaluated during those intervals. AE
adverse event, HYP high-yield process, IFN interferon, IM
intramuscular
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than in those with no medical history of these
conditions in both the daclizumab HYP
(history: 56%, 85/152 vs no history: 34%,
259/767) and IM IFN beta-1a (history: 35%,
58/164 vs no history: 16%, 118/758) groups.
Cutaneous AEs represented 30% (43/142) and
6% (7/112) of all AE-related treatment
discontinuations and 23% (15/64) and 6% (4/66)
ofAE-relatedstudywithdrawals in thedaclizumab
HYP and IM IFN beta-1a groups. Cutaneous AEs
led to treatment discontinuation in a higher
percentage of daclizumab HYP-(5%) versus IM
IFNbeta-1a-treated (\1%)patients (Table 2).Most
patients with cutaneous AEs had no action taken
with their study drug as a result of the event
(daclizumab HYP, 80.5%; IM IFN beta-1a, 89.8%;
Table 2).
The majority of patients with cutaneous AEs
had events that were mild or moderate in
severity (daclizumab HYP: 94%, 323/344; IM
IFN beta-1a: 98%, 173/176). The most common
mild and moderate cutaneous AEs (C2% of
patients in either treatment group) are listed in
Table 3. Severe cutaneous AEs were more
Table 1 Incidence of cutaneous AEs that occurred in
C2% of either treatment group
MedDRA High Level
Term, n (%)
Preferred Term
IM IFN
beta-1a
(n5 922)
Daclizumab
HYP
(n5 919)
Dermatitis and
eczema
51 (6) 133 (14)
Eczema 13 (1) 40 (4)
Seborrhoeic
dermatitis
4 (\1) 28 (3)
Dermatitis 8 (\1) 20 (2)
Allergic dermatitis 5 (\1) 19 (2)
Contact dermatitis 14 (2) 16 (2)
Atopic dermatitis 3 (\1) 14 (2)
Rashes, eruptions,
and exanthems
33 (4) 89 (10)
Rash 26 (3) 64 (7)
Maculopapular rash 4 (\1) 17 (2)
Dermal and
epidermal
conditions
12 (1) 38 (4)
Dry skin 6 (\1) 22 (2)
Acnes 11 (1) 32 (3)
Acne 9 (\1) 29 (3)
Erythemas 14 (2) 32 (3)
Erythema 14 (2) 28 (3)
Pruritus 16 (2) 32 (3)
Pruritus 15 (2) 25 (3)
Urticarias 17 (2) 24 (3)
Urticaria 15 (2) 19 (2)
Exfoliative
conditions
4 (\1) 20 (2)
Papulosquamous
conditions
5 (\1) 19 (2)
Psoriatic conditions 3 (\1) 18 (2)
Psoriasis 2 (\1) 14 (2)
Table 1 continued
MedDRA High Level
Term, n (%)
Preferred Term
IM IFN
beta-1a
(n5 922)
Daclizumab
HYP
(n5 919)
Apocrine and eccrine
gland disorders
12 (1) 17 (2)
Alopecias 9 (\1) 16 (2)
Alopecia 9 (\1) 16 (2)
Patients were only counted once with each High Level
Term/Preferred Term. Cutaneous AEs listed in
descending order in the daclizumab HYP group
AE adverse event, HYP high-yield process, IFN interferon,
IM intramuscular, MedDRA Medical Dictionary for
Regulatory Activities
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frequent in daclizumab HYP-(2%) versus IM IFN
beta-1a-treated (\1%) patients (Table 3). The
median (range) onset to first moderate or severe
cutaneous AE was 413 (1–1121) days in the
daclizumab HYP group and 311 (2–1033) days
in the IM IFN beta-1a group. When evaluated by
12-week intervals, the rate of appearance of
moderate or severe cutaneous AEs was steady
over 96 weeks in both treatment groups
(Fig. 1b); however, the overall incidence of
moderate or severe cutaneous AEs was higher
with daclizumab HYP than with IM IFN beta-1a
over the duration of the study (see Figure S1).
Based on currently available evidence, there is
no clear association between cutaneous AEs and
efficacy in daclizumab HYP-treated patients
(data on file [Biogen]). Visual examples of
mild, moderate, and severe cutaneous AEs in
daclizumab HYP-treated patients are shown in
Figure S2.
Resolution and Management
A total of 670 cutaneous AEs were reported in
the daclizumab HYP group and 247 cutaneous
AEs in the IM IFN beta-1a group. Most
cutaneous AEs were reported as resolved in the
daclizumab HYP (78%, 525/670) and IM IFN
beta-1a (82%, 203/247) groups. In the
daclizumab HYP and IM IFN beta-1a groups,
144/190 (76%) and 56/66 (85%) moderate
cutaneous AEs and 18/23 (78%) and 1/3 (33%)
severe cutaneous AEs were reported as resolved.
Most patients with mild cutaneous AEs
(daclizumab HYP: 81%, 155/191; IM IFN
beta-1a: 87%, 106/122) or moderate cutaneous
AEs (daclizumab HYP: 72%, 95/132; IM IFN
beta-1a: 73%, 37/51) did not require treatment
with corticosteroids or were treated with topical
corticosteroids (Fig. 2). In patients with severe
cutaneous AEs, 81% (17/21) of daclizumab
HYP-treated patients and 33% (1/3) of IM IFN
beta-1a-treated patients received systemic
corticosteroids (Fig. 2).
Serious Cutaneous AEs
Serious cutaneous AEs were reported in 14 (2%)
daclizumab HYP-treated patients and one (\1%)
IM IFN beta-1a-treated patient. In the
Table 2 Study action taken with study drug as a result of cutaneous AEs
Study action, n (%) IM IFN beta-1a Daclizumab HYP
Patients randomized to treatment 922 (100) 919 (100)
Cutaneous AE that led to discontinuation of study drug 7 (0.8) 43 (4.7)
Cutaneous AE that led to study withdrawal 4 (0.4) 15 (1.6)
Patients with a cutaneous AE 176 (100) 344 (100)
No action take as a result of cutaneous AE 158 (89.8) 277 (80.5)
Cutaneous AE that led to dose interruption 11 (6.3) 24 (7.0)
Cutaneous AE that led to withdrawal of study drug 7 (4.0) 43 (12.5)
The categories are mutually exclusive, and an event was counted in only one category starting with the worst category as
follows: drug withdrawn, then dose interrupted, then no action
AE adverse event, HYP high-yield process, IFN interferon, IM intramuscular
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daclizumab HYP group, dermatitis and
angioedema were reported by the investigators
in three and two patients, respectively; all other
serious cutaneous AEs were reported in one
patient each (Table 4). The serious cutaneous AE
in the IM IFN beta-1a group was reported as an
oral sebaceous cyst considered unrelated to
study treatment in a patient with a history of
cigarette smoking who was admitted to the
hospital for removal of the cyst (Table 4).
Among serious cutaneous AEs in the
daclizumab HYP group, investigators classified
ten as severe, two moderate, and two mild in
severity, and three as not related to study drug
(Table 4). In the daclizumab HYP group, six
patients discontinued treatment due to a
serious cutaneous AE but remained in the
study, and two patients withdrew from the
study due to a serious cutaneous AE but
continued to be monitored (Table 4). All
Table 3 Cutaneous AEs by severity
MedDRA Preferred Term IM IFN
beta-1a
(n5 922)
Daclizumab
HYP
(n5 919)
Any mild cutaneous AEa 122 (13) 191 (21)
Rash 21 (2) 47 (5)
Eczema 9 (\1) 30 (3)
Dry skin 4 (\1) 20 (2)
Erythema 14 (2) 18 (2)
Seborrhoeic dermatitis 2 (\1) 18 (2)
Acne 9 (\1) 17 (2)
Pruritus 14 (2) 17 (2)
Any moderate cutaneous AEa 51 (6) 132 (14)
Rash 5 (\1) 15 (2)
Any severe cutaneous AE 3 (\1) 21 (2)
Dermatitis 0 3 (\1)
Maculopapular rash 0 3 (\1)
Rash 0 2 (\1)
Angioedema 0 1 (\1)
Atopic dermatitis 0 1 (\1)
Decubitus ulcer 0 1 (\1)
DRESS 0 1 (\1)
Dry skin 0 1 (\1)
Eczema 0 1 (\1)
Erythema 0 1 (\1)
Erythema multiforme 0 1 (\1)
Erythrodermic psoriasis 0 1 (\1)
Exfoliative dermatitis 0 1 (\1)
Lichenoid keratosis 0 1 (\1)
Pityriasis rubra pilaris 0 1 (\1)
Psoriasis 0 1 (\1)
Seborrhoeic dermatitis 0 1 (\1)
Toxic skin eruption 0 1 (\1)
Table 3 continued
MedDRA Preferred Term IM IFN
beta-1a
(n5 922)
Daclizumab
HYP
(n5 919)
Guttate psoriasis 1 (\1) 0
Rosacea 1 (\1) 0
Urticaria 1 (\1) 0
AE adverse event, DRESS drug reaction with eosinophilia
and systemic symptoms, HYP high-yield process, IFN
interferon, IM intramuscular, MedDRA Medical
Dictionary for Regulatory Activities
a Mild and moderate cutaneous AEs in C2% of patients in
either treatment group. For each Preferred Term, a patient
was only counted once under the greatest severity.
However, within a given severity rating, a patient may
have experienced more than one cutaneous AE reported
under different Preferred Terms but with the same
severity. Cutaneous AEs listed in descending order in the
daclizumab HYP group
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serious cutaneous AEs resolved. Patients with
serious cutaneous AEs in the daclizumab HYP
group were frequently treated with systemic
corticosteroids (Fig. 2).
One case of drug reaction with eosinophilia
and systemic symptoms (DRESS) was reported
in a patient who had previously discontinued
daclizumab HYP 128 days before the onset of
the serious AE. The patient was treated with
short tapers of betamethasone (maximum dose
of 2.5–5.0 mg [equivalent to 21–42 mg of
prednisone]) or betamethasone 0.5 mg (4-mg
prednisone equivalent) before being
hospitalized for a worsening rash. In the
hospital, the patient was treated with
high-dose corticosteroids and one course of
plasma exchange consisting of one treatment.
The event resolved. The blinded independent
central dermatologist considered the event to
more likely represent a grade 2 delayed-type
hypersensitivity cutaneous reaction based on
the available information. A broad search of the
clinical database was conducted, and no
additional cases were found that met the
RegiSCAR criteria [10] for DRESS based on
medical review of the cases.
Fig. 2 Corticosteroid treatment in patients with cutaneous AEs by AE severity and for serious cutaneous AEs. AE adverse
event, HYP high-yield process, IFN interferon, IM intramuscular
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Table 4 Serious cutaneous AEs
Treatment group
MedDRA Preferred Term
(investigator term)
Severity No. of
doses
at onset
History of
dermatologic
condition
Action taken as a result
of serious cutaneous
AE
Related to study druga
Daclizumab HYP
Dermatitis (dermatitis) Severe 3 NR Withdrew from study
Dermatitis (interface dermatitis) Severe 13 Yes (psoriasis rash) Study drug permanently
discontinued
Dermatitis (toxic dermatitis) Severe 4 NR Noneb
Angioedema (hypersensitivity
reaction like as Quincke’s
edema)
Mild 16c NR Noned
DRESS (toxic dermatitis/DRESS
syndrome)
Severe 4 NR Noneb
Leukocytoclastic vasculitis (necrotizing
leukoytoclastic vasculitis)
Moderate 17 NR Study drug permanently
discontinued
Lichenoid keratosis
(generalized lichenoid
reaction)
Severe 17 NR Study drug permanently
discontinued
Pityriasis rubra pilaris
(pityriasis rubra pilaris)
Severe 9 Yes (allergic rash to
penicillin, latex)
Study drug permanently
discontinued
Pustular psoriasis (pustulosis of
palms and plantas)
Moderate 6 NR Withdrew from study
Maculopapular rash (diffuse
maculopapular rash)
Severe 25 NR Study drug permanently
discontinued
Toxic skin eruption (toksikodermiya
unclear origin)
Severe 22 NR Study drug permanently
discontinued
Not related to study druga
IM IFN beta-1a
Dermal cyst (sebaceous cyst of the
sublingual area)
Moderate 137 NR Noned
Daclizumab HYP
Angioedema (face angioedema with
urticaria)
Severe 9 NR Noned
Decubitus ulcer (bed sore) Severe 4 NR Nonee
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Adjudication by Blinded Dermatologist
Based on the evaluation of cutaneous AEs in
DECIDE, the central dermatologist concluded
that daclizumab HYP was associated with an
increased risk of cutaneous AEs. The central
dermatologist reviewed and provided
assessments for all cutaneous AEs considered
clinically significant by the investigators. Over
the course of the study, the central
dermatologist reviewed case reports for 42%
(284/670) of all cutaneous AEs in the
daclizumab HYP group and 28% (70/247) of
all cutaneous AEs in the IM IFN beta-1a group.
The overall subjective impression of the central
dermatologist was that cutaneous AEs in
DECIDE resembled eczematous or psoriasis-like
events or were typical of skin conditions
commonly encountered in a dermatology
clinic. In addition, there were a small number
of cases that were classified as delayed-type drug
hypersensitivity, most of which were
mild-to-moderate in severity. In the opinion of
the blinded central dermatologist, there were
no cases that represented life-threatening
events. There were no reported cases of
Stevens–Johnson syndrome or toxic epidermal
necrolysis.
DISCUSSION
In DECIDE, daclizumab HYP was associated
with a higher risk of cutaneous AEs over
2–3 years of treatment compared with IM IFN
beta-1a in patients with RRMS. Relevant
medical history of dermatological conditions
exacerbated this risk to a similar degree in both
treatment groups. Consistent with these
observations, the incidence of cutaneous AEs
was higher with daclizumab HYP 150 mg SC
(18%) than placebo (13%) in the 1-year SELECT
study [6]. Cutaneous AEs reported here are
distinct from injection site reactions, which
are localized and temporally linked to the
injection [11].
Consistent with these findings, a recent
open-label, prospective study has
demonstrated a high frequency of new-onset
cutaneous events associated with daclizumab
HYP administration in patients with RRMS [12].
The majority of cutaneous findings in this study
were consistent both clinically and
Table 4 continued
Treatment group
MedDRA Preferred Term
(investigator term)
Severity No. of
doses
at onset
History of
dermatologic
condition
Action taken as a result
of serious cutaneous
AE
Psoriasis (psoriasis exacerbation) Mild 19 Yes (psoriasis) Noned
AE adverse event, DRESS drug reaction with eosinophilia and systemic symptoms, HYP high-yield process, IFN interferon,
IM intramuscular, MedDRA Medical Dictionary for Regulatory Activities, NR none reported
a Relationship to study drug as assessed by the investigator
b The patient had previously discontinued treatment due to a non-serious cutaneous AE; however, no study action was
taken as a result of the serious cutaneous AE and the patient continued in the study
c The number of doses was based on an estimated date of onset because the date of onset was not reported
d The patient remained on study drug and in the study
e At the time this serious cutaneous AE was reported, the patient had been withdrawn from the study (consent withdrawn).
No study action was taken as a result of the serious cutaneous AE. The patient had a brain stem relapse before the onset of
this serious cutaneous AE and subsequently died as a result of aspiration pneumonia
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histologically with an eczematous dermatitis
[12]. In biopsies, cellular infiltrates in the
epidermis and dermis consisted of abundant T
cells, and immunohistochemistry revealed
increased expression of CD56, highlighting
either NK cells or CD8? T cells amongst them
[12]. The authors suggested that cutaneous
events represent pharmacologic (mechanistic)
immune modulation by daclizumab HYP, rather
than typical drug hypersensitivity-type
reactions [12]. A previous chart review study
identified a case of alopecia following the
development of a severe exfoliative rash in a
patient treated with intravenous daclizumab
(Zenapax, Roche Laboratories, Nutley, NJ,
USA) [13]. Both the rash and alopecia resolved
following discontinuation of daclizumab and
corticosteroid treatment [13]. In the DECIDE
study, alopecia was reported in 16 (2%) patients
in the daclizumab HYP group (see Table 1). All
of these cases of alopecia were mild or moderate
in severity; no cases of severe alopecia were
reported (see Table 3).
A strength of DECIDE was the inclusion of a
blinded central dermatologist, which allowed
for accurate monitoring and assessment of
cutaneous AEs. One limitation of this study
was that very few biopsies were performed on
cutaneous lesions. Results from biopsies may
have provided valuable information to better
understand the nature of the cutaneous AEs. In
addition, photographs of cutaneous AEs were
limited in number and some were of insufficient
quality to be useful. Interpretation of the rates
of resolution of cutaneous AEs in both
treatment groups may be limited by the
background rate of chronic dermatologic
conditions known to occur in both the general
population and in patients with MS [14, 15] and
by incomplete data in patients who withdrew
from the study with an ongoing non-serious AE.
Because investigators were provided with
cutaneous event guidelines and were made
aware of this type of AE, a higher treatment
rate with corticosteroids may have resulted
from the distribution of these guidelines.
The potential link between the underlying
mechanisms of daclizumab HYP and cutaneous
AEs is unclear. Skin-resident regulatory T (Treg)
cells may counteract inflammatory T cell
responses, and alterations in Treg cell function
in the skin have been observed in psoriasis [16].
CD25 blockade results in both expansion of
CD56bright natural killer cells [17, 18] and
reversible declines in the number of
circulating Treg cells in patients with RRMS
[19, 20]. Treg cells remaining in circulation
during CD25 blockade appeared to preserve
the Treg phenotype [19], although reductions
in suppressive capacity have been observed [20].
As such, the relationship between reductions in
Treg cells and cutaneous AEs during CD25
blockade is currently inconclusive [19, 20].
Additional work is required to determine
whether compartmental differences exist in
the maintenance of organ-specific
self-tolerance by Treg cells [20].
Early recognition and treatment of
inflammatory skin conditions offers the best
chance for reversing or limiting flares of the
disease [21, 22]. Dermatologic treatment
guidelines recommend topical agents,
including moisturizers and topical
corticosteroids, for psoriasis and eczema
[23, 24]. Moisturizers maintain skin hydration
and can reduce itching [23]. Topical
corticosteroids are recommended to decrease
inflammation, and numerous formulations are
available that range in relative potency (see
Table S2) [23, 24]. Higher-potency topical
corticosteroids are generally recommended as
the initial therapy for acute flares on most body
parts in adults, and lower-potency agents for
maintenance therapy [23, 24]. Topical
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treatments, including corticosteroids, are also
recommended for use with systemic treatments
in more extensive eczema or psoriasis [23, 24].
Systemic corticosteroids are only recommended
for acute severe exacerbations of eczema [25],
and are generally contraindicated in psoriasis
[26]. The overall pattern of corticosteroid
treatment for cutaneous AEs in DECIDE was
generally consistent with these treatment
guidelines, wherein topical corticosteroids
were more frequently used for mild and
moderate cutaneous AEs and systemic
corticosteroids for severe or serious events.
Dermatologic Perspectives of Daclizumab
HYP-Related Cutaneous AEs
For the range of cutaneous AEs observed in both
treatment groups in DECIDE, one must have an
understanding of the overall frequency of skin
diseases across world populations and the
function of skin as an immunologic organ in
both health and disease. Surveys have shown
that eight of the most common medical
problems in humans are skin conditions [27],
including eczema, which was a frequent
investigator-reported diagnosis in DECIDE.
Atopic eczema is also a common skin
condition in up to 30% of children, where the
majority outgrow eczema by early adulthood
but there is also an increasing frequency of
adult-onset atopic eczema across world
populations [21, 28, 29]. Hence, one
perspective is that a large range of common
skin conditions are also seen in the DECIDE
study population. Within the spectrum of
cutaneous AEs in DECIDE, there was a large
representation of eczema and eczema-spectrum
conditions (i.e., allergic dermatitis, eczema,
nummular dermatitis, and hand dermatitis)
[29], which may be classified as inflammatory
skin diseases. Among patients with cutaneous
AEs, more than one-third (133/344 [39%]) had
investigator-reported AEs coded to the MedDRA
High Level Term dermatitis and eczema (see
Table 1). Although eczematous events are a
nuisance, they typically tend to be reversible
and do not result in skin damage or organ
failure even if present for extended periods
[26, 30]. Chronic rashes are likely driven by the
interplay between genetic predisposition,
immune response, and environmental factors
(e.g., tendency for re-emergence of eczema in
humans) [22]. Importantly, daclizumab HYP did
not lead to cutaneous AEs that resulted in loss of
skin structure or function. Most cutaneous AEs
during daclizumab HYP treatment were not
allergic reactions. However, a small number of
drug-type hypersensitivity reactions were
identified; these reactions need to be
distinguished from inflammatory diseases, as it
may be necessary to discontinue drugs that
drive drug-type hypersensitivity reactions.
Overall, early diagnosis and treatment of
cutaneous AEs following established
dermatologic management guidelines offer the
best opportunity for resolution.
We speculate that many of the inflammatory
skin conditions noted in DECIDE relate
mechanistically to the function of skin as an
immune organ and to mechanistic effects on
Treg cells or other regulatory immune
mechanisms. Skin contains resident dendritic
antigen-presenting cells and skin-homing
resident memory T cells; therefore, immune
reactions confined only to the skin are possible
[16, 31]. The range of commonly encountered
skin diseases, such as atopic eczema and
psoriasis, represent excessive activation of T
cells in the skin, and skin inflammation is
produced by effects of T cell-derived cytokines
on resident skin cells, in part enabled by the
reduced function of Treg cells [32]. Targeted
removal of cutaneous Treg cells in model
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systems produces skin inflammation and excess
production of cytokines that typify atopic
eczema and related diseases [33]. Hence, the
decrease in Treg cells noted in circulating T cells
during daclizumab HYP treatment [19, 20] may
well extend to diminished function of these
cells with the cutaneous compartment, leading
to unmasking or activation of resident T cell
populations that mediate psoriasis or
eczema-spectrum conditions.
CONCLUSION
In summary, cutaneous AEs in daclizumab
HYP-treated patients were predominantly
mild-to-moderate in severity, treated with
topical corticosteroids or did not require
treatment with a corticosteroid, and resolved.
More severe or serious cutaneous AEs frequently
required treatment with systemic
corticosteroids. Some patients received
multiple courses of corticosteroids when the
cutaneous AE was of longer duration. Most
importantly, the cutaneous AEs observed with
daclizumab HYP were manageable with
standard interventions and, even in the
smaller number of serious cases, did not lead
to any life-threatening conditions.
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